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At 15, Ron Germain cared for white 
mice kept on a ping-pong table in his 
basement. “You couldn’t just buy inbred 
mice at the pet store,” he recalls, “but I 
had a connection.” With his C57BL/6 
and A/J strains, he attempted to cure 
graft-versus-host disease with thymic 
transplants. His mother would supple-
ment these experiments by driving him 
to Rockefeller University, where the 
young Germain snuck into seminars on 
immunology. And so it is little surprise 
that he’s since risen through the ranks of 
T cell immunology, first at Harvard 
Medical School and later at the National 
Institutes of Health (NIH). He’s helped 
elucidate the expression, structure, and 
function of MHC class II molecules, the 
cell biology of antigen processing, and the 
molecular basis of T cell recognition (1). 
Currently, he and his team peer into the 
dynamics of immune cell 
movement using two-
photon microscopy, and 
construct mathematical 
models of T cell signaling 
and activation (2–4).
In 2006, Germain 
spearheaded a systems 
immunology program at 
the National Institute of 
Allergy and Infectious 
Diseases (NIAID), which 
included the development 
of software to build and test complex 
models. More recently he’s helped estab-
lish the Center for Human Immunology 
(CHI) at the NIH, an interdisciplinary 
effort with the goal of translating analyses 
of the human immune system into ther-
apies for immune-mediated diseases.
What strikes me about your papers, 
particularly one called “The Art of the 
Probable” (5), is your attention to 
overriding concepts and emergent 
properties in the immune system.
It’s true, I’m a conceptual person. I’m not 
so interested in ferreting out every little 
detail. I want to understand how things 
work in the larger sense. 
In my papers, I don’t tend 
to report fi  ve new trans-
genics, three knockouts, 
and 82,000 blots. That’s 
just not how I do science 
because getting data 
doesn’t necessarily give 
you important answers. 
Sometimes I’m afraid 
we’ve failed to pay atten-
tion to how the immune 
system actually works. Too 
many things are described 
in these very black-and-
white, linear ways—you 
do this and you get that. 
But that’s not biological 
reality. And that was the 
point of “The Art of the Probable”—that 
there’s more to things, like fl  uctuating 
cells states and bi-stable conditions.
How will immunologists handle the fl  ood of 
raw data spewing forth from technological 
advances?
Part of the trick will be to fi  gure out what 
data we need. Data space is infi  nite, and 
trying to fi  ll that space up won’t give you 
the key. People need to come to grips with 
the fact that you need to make the right 
measurements and combine them in ways 
that let us better understand complex 
systems. A major goal of ours is to create 
models that predict how a cell or organism 
behaves if perturbed, and to do this, we 
need particular kinds of information.
Don’t you need to generate data before 
building a model?
When people say this, I point out two 
things. First of all, as you rigorously defi  ne 
a process in order to model it, you fi  nd 
gaps in your knowledge that you’d other-
wise forget about when you’re not think-
ing discreetly. And second, if you build a 
very good model and make predictions 
with it, it can begin to tell you about 
behaviors you didn’t expect that then lead 
to new experimental avenues of research.
SCIENCE’S NEXT TOP MODEL
How can a systems biology approach 
make inroads into vaccine research?
In vaccine research, you need to com-
bine several diff  erent types of measure-
ments. People are just beginning to get a 
feel for how to accomplish this. For 
example, some investigators are doing 
extensive array and SNP [single nucleotide 
polymorphism] analyses to look at expres-
sion levels and quantitative trait loci, and 
then link these back to phenotype.
I’m very interested in such approaches 
because I think that seeing how the 
larger system behaves is an important 
goal. The whole concept behind the 
CHI is to see if we can collect the right 
types of data at the right density to 
better model and better understand the 
human immune system.
What is happening at the CHI?
The fi  rst thing that’s exciting is the level 
of inter-institute cooperation in the 
scientifi  c arena. People from multiple 
institutes are getting together and trying 
to do things that none of us could do in 
our individual laboratories. The people 
involved are donating their time and 
energy to try to get this to happen be-
cause we all believe this is important. 
As data floods in, Germain works overtime to decipher which immunological information matters and how it can be 
applied to saving lives.
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Ron Germain (center) at the two-photon microscope with 
Alex Huang (left) and Hai Qi.
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The good news also is that there are a 
number of other places outside of the 
NIH gearing up to do very similar things. 
We’re all making eff  orts to adopt com-
mon operating procedures, measurement 
styles, and data deposition approaches so 
that we can build a large database of 
qualifi  ed  fi   ndings. At the NIH, we’ve 
gotten a bit of a head start in creating 
the normal human immunome.
What’s a normal human immunome?
It’s a multi-omic characterization of the 
state of the human immune system. It’s a 
database we’re building based on results 
from expression arrays, highly multiplex 
fl   ow cytometry and cytokine assays, 
genetic analyses, and functional studies. 
We’re working on this internally across 
many institutes, we are seeking collabo-
rations with companies, and we’re in 
touch with external investigators nation-
ally and internationally.
Right now we’re looking at how 
the normal human immunome is per-
turbed by flu vaccines in nearly 200 
individuals. We get two prevaccination 
bleeds and then we do a series of early 
and late post-vaccine bleeds. We hope to 
get about 17,000 different sub-phenotype 
possibilities from the flow analyses and 
60–100 cytokine measurements on 
every one of the samples. We’ll keep 
material on reserve for later to do SNP 
chips, HLA typing, and eventually se-
quencing if it becomes cheap enough. 
The idea is to then put this all together 
in a very deep analysis.
What might it tell us?
Far more than what we know now. You 
can’t do experiments in people the way 
you do them in animals. But there are 
ethical manipulations of the human 
immune system that go on all of the time, 
whether it’s vaccination or whether it’s 
treatments for rheumatoid arthritis or 
other immune-related diseases. And so 
our goal is to measure the state of the 
normal immune system and the system as 
it gets perturbed by things like vaccines, 
infections, or therapies. As this database 
grows we can begin to relate it to geno-
type as well. It’s an ongoing goal.
With this project we’re taking the 
benefits that have come from decades of 
investment in basic research and putting 
time and energy into a larger effort that 
aims to better understand the human 
immune system. Ultimately, we want to 
use that information to rapidly improve 
health. In the flu project there are more 
than 20 investigators from different insti-
tutes helping to get this started and there 
hasn’t been a single discussion about 
authorship. It’s just a feeling that we 
should do this, we’re going to do this, 
and we’ll figure out publications later.
FATHOMING COMPLEXITY
What’s holding up vaccine development 
for neglected diseases?
It’s simply unclear how to make vaccines 
for many diseases. It’s been doable to make 
vaccines against diseases that you are 
robustly immune to if you survive the 
initial infection. However, vaccines against 
infectious agents that don’t give you 
natural immunity are diffi   cult to make, 
neglected or not. And this goes back to 
this fundamental issue of not under-
standing  the human immune response 
well enough. I think that’s one of the 
wake-up calls that’s come out of the HIV 
experience, which is that we don’t know 
exactly what we need to do. And in some 
cases, even when you know what you 
want, it’s not easy to get it to happen.
Can advances in adjuvants help?
I think everybody has fi  gured out 
that you need the right adjuvants. 
But the “dirty little secret” is that 
people don’t understand what 
makes for a good adjuvant for cer-
tain things versus others. And then 
there is a safety issue. One thing 
that is a struggle—and I’ve been on 
a number of panels this year look-
ing at this—is that there are adju-
vants permitted for use in Europe 
that are not permitted for use in the 
US. For example, an adjuvant for the 
fl  u vaccine allows you to reduce the 
dose by one third to one tenth in 
terms of total amount of antigen. 
And even at a lower dose, that ad-
juvant gives you a higher response 
more rapidly after a single booster or 
injection. But the question that still 
comes up is whether there has been 
enough post-use tracking to be sure there 
are no untoward eff  ects 
in terms of say, autoim-
munity. And that’s almost 
unanswerable in short-
term trials because in very 
large populations you will 
fi  nd a certain number of 
autoimmune events that 
occur after getting vacci-
nated because statistically, 
some people will have 
autoimmune events.
The next question is 
what is the risk–benefit 
ratio? If there are diseases 
that have high morbidity, 
which you can only pre-
vent with adjuvants in 
vaccines, then a slight risk 
compared with doing nothing at all is still 
a huge benefit. You have to look at that 
balance. The question is how to get the 
data to know what that balance is. It’s all 
very, very complicated. Hopefully, the 
CHI will help.
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The migration patterns of transgenic T cells (tracks 
in red and green) in follicles (blue) can be mapped 
with intravital two-photon microscopy.
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“For diseases 
that have high 
morbidity, 
which you can 
only prevent 
with adjuvants 
in vaccines, 
then a slight 
risk compared 
to doing 
nothing at all 
is still a huge 
benefit.”